Thoracic Oncology Unit (Lung Cancer Unit)

Specialized in the diagnosis and treatment of thoracic malignancies, the Lung Cancer Unit manages a complex group of diseases that require a high level of expertise and close coordination among multiple medical specialties.

The unit’s approach is based on precision medicine, using molecular and genetic profiling of tumors to personalize treatment for each patient, maximizing effectiveness while minimizing potential side effects.

The unit brings together specialists from the Rosell Oncology Institute (IOR) and the Barcelona Oncology Institute (IOB), combining clinical expertise, research, and advanced diagnostic capabilities. This model enables a comprehensive approach to patient care, supported by molecular analysis and the application of personalized therapies based on the latest scientific evidence.

Medical Team

Dr. Jaume Pujadas (Medical Oncologist)
Dra. Roxana Reyes (Medical Oncologista)

Diagnosis

The diagnosis of lung cancer is based on a comprehensive clinical evaluation, histological confirmation of the tumor, and assessment of its extent and molecular characteristics.

Initially, a clinical assessment and imaging studies are performed to identify potential lung lesions.

The main diagnostic procedures include:

Imaging Studies

• Chest X-ray
• Thoracic Computed Tomography (CT) scan
• Positron Emission Tomography (PET) scan to assess the extent of the disease

Diagnostic Confirmation

• Tumor biopsy for histopathological analysis
• Procedures such as bronchoscopy or image-guided biopsy

Molecular Analysis

• Assessment of tumor genetic alterations
• Genomic profiling platforms and liquid biopsy in selected cases

Additional Evaluation

• Comprehensive laboratory testing, including tumor markers
• Additional investigations according to the stage of the disease

Molecular analysis plays a key role in identifying specific genetic alterations that can guide the selection of targeted therapies and support a personalized treatment strategy.

Treatments

The treatment of lung cancer is based on a multidisciplinary approach that combines different therapeutic strategies according to the tumor type, disease stage, and individual patient characteristics.

The main treatment options include:

• Thoracic surgery (tumor resection in early-stage disease)
• Radiation therapy
• Chemotherapy
• Immunotherapy
• Targeted therapies based on specific molecular alterations

In selected cases, treatment may begin with systemic therapies before surgery, or multiple treatment modalities may be combined to optimize clinical outcomes.

Advances in precision medicine have made it possible to identify specific genetic alterations within tumors (such as mutations involving KRAS, EGFR, ALK, and others), facilitating the selection of more effective and personalized treatment options.

Research and Clinical Trials

The unit actively participates in national and international clinical trials in lung cancer, providing access to innovative treatments and emerging therapeutic strategies across different stages of the disease.

These studies contribute to advances in targeted therapies, immunotherapy, and combination treatment approaches, helping to improve clinical outcomes and patients’ quality of life.

Approach and Services

• Specialized management of lung cancer, with close coordination between medical oncology and other relevant specialties
• Personalized medicine based on the biological characteristics of the tumor
• Comprehensive patient assessment
• Support and guidance throughout the entire care journey
• Clinical follow-up focused on the early detection of potential recurrence